Monoclonal antibodies (m Abs) are naturally occurring complex biomolecules. New engineering methods have turned m Abs into a leading therapeutic modality for addressing immunotherapeutic challenges and led to the rise of m Abs as the dominant class of protein therapeutics. m Abs have already demonstrated a great potential in developing safe and reliable treatments for complex diseases and creating more affordable healthcare alternatives. Developing m Abs into well-characterized antibody therapeutics that meet regulatory expectations, however, is extremely challenging. Obstacles to overcome include the determination and development of physiochemical characteristics such as aggregation, fragmentation, charge variants, identity, carbohydrate structure, and higher-order structure (HOS). This book dives deep into m Abs structure and the array of physiochemical testing and characterization methods that need to be developed and validated to establish a m Ab as a therapeutic molecule. The main focus of this book is on physiochemical aspects, including the importance of establishing quality attributes such as glycosylation, primary sequence, purity, and HOS and elucidating the structure of new antibody formats by mass spectrometry. Each of the aforementioned quality attributes has been discussed in detail; this will help scientists in researching and developing biopharmaceuticals and biosimilars to find practical solutions to physicochemical testing and characterization. – Describes the spectrum of analytical tests and characterization methods necessary for developing and releasing m Ab batches- Details antibody heterogeneity in terms of size, charge, and carbohydrate content- Gives special focus to the structural analysis of m Abs, including mass spectrometry analysis- Presents the basic structure of m Abs with clarity and rigor- Addresses regulatory guidelines – including ICH Q6B – in relation to quality attributes- Lays out characterization and development case studies including biosimilars and new antibody formats